OVIT (OncoVista Innovative Therapies) Other Long-Term Liabilities: $0.00 Mil (As of Sep. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is OncoVista Innovative Therapies Other Long-Term Liabilities?

OncoVista Innovative Therapies OVIT Other Long-Term Liabilities is $0.00 Mil as of Sep. 2015.

OncoVista Innovative Therapies's other long-term liabilities for the quarter that ended in Sep. 2015 was $0.00 Mil.

OncoVista Innovative Therapies's quarterly other long-term liabilities declined from Mar. 2015 ($0.70 Mil) to Jun. 2015 ($0.00 Mil) but then stayed the same from Jun. 2015 ($0.00 Mil) to Sep. 2015 ($0.00 Mil).

OncoVista Innovative Therapies's annual other long-term liabilities stayed the same from Dec. 2012 ($0.00 Mil) to Dec. 2013 ($0.00 Mil) but then increased from Dec. 2013 ($0.00 Mil) to Dec. 2014 ($0.70 Mil).

OncoVista Innovative Therapies Other Long-Term Liabilities Related Terms

OncoVista Innovative Therapies Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for OncoVista Innovative Therapies's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoVista Innovative Therapies Other Long-Term Liabilities Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.70

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.70 0.70 0.00 0.00

OncoVista Innovative Therapies Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $0.00 Mil mean?
OncoVista Innovative Therapies (OVIT) has a Other Long-Term Liabilities of $0.00 Mil as of Sep. 2015. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on OncoVista Innovative Therapies and its competitors.
Is OncoVista Innovative Therapies' Other Long-Term Liabilities too high?
OncoVista Innovative Therapies' current Other Long-Term Liabilities is $0.00 Mil.
How does OncoVista Innovative Therapies' Other Long-Term Liabilities compare to RSPI and HSTC?
OncoVista Innovative Therapies' Other Long-Term Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on OncoVista Innovative Therapies and its competitors. OncoVista Innovative Therapies's current Other Long-Term Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoVista Innovative Therapies stock overvalued right now?
OncoVista Innovative Therapies (OVIT) has a current Other Long-Term Liabilities of $0.00 Mil. The current Other Long-Term Liabilities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For OncoVista Innovative Therapies (OVIT), the current Other Long-Term Liabilities is $0.00 Mil as of Sep. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoVista Innovative Therapies Business Description

Address 14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.